Skip to main content
Fig. 5 | BMC Complementary Medicine and Therapies

Fig. 5

From: Mitigation of intrahepatic cholestasis induced by 17α-ethinylestradiol via nanoformulation of Silybum marianum L.

Fig. 5

Effect of SM or nano-SM on hepatic (A) ROCK 1, (B) MLCK, and (C) MYPT1 expressions. The results are presented as means ± SE.a, b, c, d Significant difference from normal, EE, EE + UDCA, and EE + SM group sat p < 0.05, respectively. EE: 17α-ethinylestradiol; UDCA: Ursodeoxycholic acid; SM: Silybum marianum L.; ROCK: Rhokinase 1, MLCK: myosin light chain kinase, MYPT1: myosin phosphatase target subunit

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us